

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael J. Taylor et al.                      Art Unit : Unknown  
Serial No. :    Examiner : Unknown  
Filed :  
Title : BOVINE TUMOR NECROSIS FACTOR RECEPTOR-1 AND METHODS OF  
USE

**BOX PATENT APPLICATION**

Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the Specification:

Please insert the following paragraph on page 1 of the application after the title:

**--CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a divisional of and claims priority under 35 U.S.C. §120 to U.S.  
Application No. 09/513,007, filed February 25, 2000.--

Please insert the enclosed Sequence Listing into the application after the Figures.

In the Claims:

Please cancel claims 1-14, 16, 18, and 20-28.

A complete set of pending claims, including new claims 29-34, is as follows:

15. A purified polypeptide, wherein said polypeptide comprises a bovine TNF-RI.
17. The polypeptide of claim 15, wherein said polypeptide is a soluble bovine TNF-RI.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 639959829US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

October 3, 2001  
Date of Deposit

Signature

Vince Defante

Typed or Printed Name of Person Signing Certificate

19. The polypeptide of claim 17, wherein said polypeptide comprises a bovine TNF-RI extracellular domain or fragments thereof.

29. A purified bovine TNF-RI polypeptide that binds TNF, wherein said polypeptide is encoded by a nucleic acid selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO.:1;
- (b) a fragment of the nucleotide sequence of (a); and
- (c) a nucleotide sequence that is at least 85% identical to (a) or (b).

30. A purified soluble bovine TNF-RI polypeptide that binds TNF, wherein said polypeptide is encoded by a nucleic acid selected from the group consisting of :

- (a) the nucleotide sequence of SEQ ID NO.:3,
- (b) a fragment of the nucleotide sequence of (a); and
- (c) a nucleotide sequence that is at least 85% identical to (a) or (b).

31. The polypeptide of claim 30, wherein said polypeptide comprises a bovine TNF-RI extracellular domain or fragments thereof.

32. A purified bovine TNF-RI, wherein said polypeptide is selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:2; and
- (b) a fragment of the polypeptide of (a) that binds TNF.

33. A purified soluble bovine TNF-RI, wherein said polypeptide is selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:4; and
- (b) a fragment of the polypeptide of (a) that binds TNF.

34. The polypeptide of claim 33, wherein said polypeptide comprises a bovine TNF-RI extracellular domain or fragments thereof.

FILED " 3654660

REMARKS

Applicants respectfully request entry of the amendments and remarks submitted herein. Claims 15, 17, and 19 have been amended and new claims 29-34 have been added. Support for the amendments and the new claims can be found in the originally filed claims and throughout the specification. Attached is a marked-up version of the changes being made by the current amendments. Consideration of the pending application in view of the claim amendments is respectfully requested.

Applicants note that claims 15, 17, and 19 correspond to Group II in the April 11, 2001 Restriction Requirement issued by the Examiner in the parent application, U.S. Application No. 09/513,007. New claims 29 and 30 closely parallel claims 1 and 11 in the parent case. Based upon the Office Action mailed July 13, 2001 in the parent application and Applicants' claim amendments in the Response of September 12, 2001, Applicants are expecting a Notice of Allowance for such parallel claims in the parent application.

CONCLUSION

Applicant asks that claims 15, 17, 19, and 29-34 be examined. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

October 3, 2001



M. Angela Parsons, Ph.D.  
Reg. No. 44,282

Fish & Richardson P.C., P.A.  
60 South Sixth Street  
Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Facsimile: (612) 288-9696  
60054200.doc

In the Specification:

The application was amended to contain a Sequence Listing.

Claims 1-14, 16, 18, and 20-28 have been cancelled.

15. (Amended) A purified [An isolated] polypeptide, wherein said polypeptide comprises a bovine TNF-RI.

17. (Amended) The [isolated] polypeptide of claim 15, wherein said polypeptide [encodes] is a soluble bovine TNF-RI.

29. A purified bovine TNF-RI polypeptide that binds TNF, wherein said polypeptide is encoded by a nucleic acid selected from the group consisting of:

30. A purified soluble bovine TNF-RI polypeptide that binds TNF, wherein said polypeptide is encoded by a nucleic acid selected from the group consisting of :

31. The polypeptide of claim 30, wherein said polypeptide comprises a bovine TNF-RI extracellular domain or fragments thereof.

32. A purified bovine TNF-RI, wherein said polypeptide is selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:2; and
- (b) a fragment of the polypeptide of (a) that binds TNF.

33. A purified soluble bovine TNF-RI, wherein said polypeptide is selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:4; and
- (b) a fragment of the polypeptide of (a) that binds TNF.

34. The polypeptide of claim 33, wherein said polypeptide comprises a bovine TNF-RI extracellular domain or fragments thereof.

08411-018002